Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACR-368 in Endometrial Cancer
NCT05548296Phase 2Recruiting
- Sponsor
- Acrivon Therapeutics, Inc.
- Start
- Aug 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of prexasertib in endometrial adenocarcinoma, sponsored by Acrivon Therapeutics, Inc.. Started Aug 2022; status: recruiting.
02
Drugs
prexasertib
03
Conditions
endometrial adenocarcinoma
Beyond the preview
Go deeper on NCT05548296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548296.